▎WuXiEdited by the Kant Content Team

Development of Multi-Payload Antibody-Drug Conjugates: Sino-Foreign Pharma Collaboration Reaches Nearly $800 Million in R&D Partnership

Araris Biotech today announced that it has reached a research collaboration and license option agreement with Chugai Pharmaceutical Co., Ltd. ("Chugai Pharmaceutical"), a subsidiary of Roche. According to the agreement,Araris will leverage its proprietary linker conjugation platform, AraLinQ, in conjunction with antibodies targeting undisclosed antigens provided by Chugai Pharmaceutical, to develop novel antibody-drug conjugates (ADCs).。

According to the terms of the agreement, Chugai will pay an upfront fee, fund all research activities, and assume sole responsibility for subsequent development, manufacturing, and global commercialization activities after exercising the license option. Upon Chugai's achievement of certain development, regulatory, and commercial milestones, Araris will be eligible to receive milestone payments of approximately $780 million.

Araris Biotech's proprietary conjugation technology can link payloads to specific amino acids on antibodies without modifying the antibodies. This technology enables the conjugation of multiple synergistic anti-cancer payloads to a single antibody through an efficient one-step reaction.Araris is developing a new generation of "smart missiles" to potentiate chemotherapy combinations in a targeted manner, addressing long-standing challenges such as cancer drug resistance. This innovative approach aims to provide enhanced safety and efficacy, offering patients more precise treatment options.

Development of Bispecific Antibody-Drug Conjugates Carrying Dual Payloads: New Collaboration Established

Biocytogen and Acepodia Announce Strategic Collaboration to Develop a Bispecific Antibody-Drug Conjugate with Dual Payloads (BsAD2C)This collaboration will combine Biocytogen's RenLite platform with Acepodia's Antibody Double Drug Conjugate (AD2C) technology to address the most challenging issues in the field of oncology—tumor heterogeneity and drug resistance. This innovative approach aims to tackle these complex problems by leveraging dual payloads targeting multiple therapeutic or disease pathways. These payloads are delivered via bispecific antibodies, achieving higher precision and functionality.

According to the strategic cooperation agreement, Biocytogen will provide bispecific antibodies generated by its proprietary RenLite platform. This platform is designed to produce fully humanized bispecific antibodies with unique binding properties. Acepodia will integrate two different payloads into this antibody through its AD2C platform.The AD2C platform utilizes bioorthogonal click chemistry technology, which does not require antibody engineering modifications. This ensures the integrity and binding capability of the antibodies while enabling precise control over the drug-to-antibody ratio (DAR), thereby optimizing both drug efficacy and safety.

Sanofi Reaches Over $400 Million R&D Collaboration Targeting Central Nervous System

Alloy Therapeutics Announces Target-Specific Collaboration and License Agreement with Sanofi to Develop CNS Drugs Using Proprietary AntiClastic Platform

Alloy Therapeutics' AntiClastic antisense platform fully unlocks the potential of antisense therapy by targeting intracellular disease targets at the RNA level. This platform overcomes the limitations of current antisense therapies in terms of therapeutic index.This technology platform was launched by Alloy Therapeutics in 2023, based on an innovative oligonucleotide conformation design developed by Dr. Sudhir Agrawal of Arnay Sciences.

▲To learn more about the application of cutting-edge technologies in the biopharmaceutical industry, please long press and scan the QR code above to access "WuXi Live Studio" and watch live discussions and exciting replays on related topics.